Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2007

View Archived Issues

Recent clinical data on nilotinib in leukemia presented

Snapshots of agents under study in Alzheimer's disease

Malaria vaccine AMA1 studied in phase Ib trial in Mali

New results with therapies under development for Parkinson's disease

Recent Tibotec and Bristol-Myers Squibb patents report novel therapeutic agents for HIV infection

New agents for treating neurological disorders disclosed in recent patent literature

Recent patents report novel therapeutic agents for metabolic disorders

NOV-002 slows disease progression in platinum-resistant ovarian cancer

Positive topline findings for balsalazide tablets

FDA grants orphan drug status to Immtech's pafuramidine

Keryx completes patient randomization for Sulonex phase III study

Chugai to explore safety of oseltamivir

Findings for new powder form of Renvela

IC31 adjuvanted flu vaccine begins phase I trials

Lexicon announces long-term financial agreements with Invus and Symphony

Peptech restructures agreement with Biosceptre

Sativex receives Qualifying Notice from Health Canada for cancer pain

Genta to request review of Genasense's non-approvable status

Collegium files IND for abuse deterrent opioid COL-003

Terutroban exhibits beneficial effects in rat models of stroke

FDA accepts for review GlaxoSmithKline's DTaP-IPV combination vaccine

Preclinical studies on drugs under development for Parkinson's disease

Telcyta clinical hold converted to partial hold

Nexavar submitted in E.U. for hepatocellular carcinoma

Ixabepilone NDA granted priority review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...